Table 3.
Frequencies of drug-AE pairs and reporting rate according to the drug class by gender, and its ratio of women to men.
| Drug class | Women (N = 8469) | Men (N = 7200) | Risk ratiob (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| Number of drug user | Drug-AE pairs | Reporting ratea | Number of drug user | Drug-AE pairs | Reporting ratea | ||
| GLP-1RA | 3167 | 193 | 609.5 | 2800 | 73 | 260.7 | 2.34 (1.79–3.05) |
| SGLT2 inhibitors | 72,400 | 482 | 66.6 | 78,767 | 233 | 29.6 | 2.25 (1.93–2.63) |
| Thiazolidinedione | 145,500 | 221 | 15.2 | 203,033 | 196 | 9.7 | 1.57 (1.30–1.91) |
| Insulin | 245,800 | 4919 | 200.1 | 281,267 | 3901 | 138.7 | 1.44 (1.38–1.50) |
| Sulfonylurea | 660,133 | 1096 | 16.6 | 834,033 | 1090 | 13.1 | 1.27 (1.17–1.38) |
| Metformin | 1,210,667 | 2530 | 20.9 | 1,482,000 | 2445 | 16.5 | 1.27 (1.20–1.34) |
| DPP-4 inhibitors | 812,667 | 1493 | 18.4 | 1,045,533 | 1602 | 15.3 | 1.20 (1.12–1.29) |
| Others | 11,633 | 189 | 162.5 | 12,767 | 188 | 147.3 | 1.10 (0.90–1.35) |
| α-glucosidase inhibitors | 54,533 | 146 | 26.8 | 59,733 | 177 | 29.6 | 0.90 (0.73–1.12) |
Combination drugs were included in each drug class by corresponding ingredients.
AE adverse event, CI confidence interval, GLP-1RA glucose like peptide-1 receptor analogues, SGLT2 inhibitors sodium-glucose co-transporter 2 inhibitors, DPP4i dipeptidyl peptidase 4 inhibitors.
aReporting rate per 10,000 people was calculated over the total number of drug users of each class.
bReporting ratio = reporting rate of women/ reporting rate of men.